Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

De Angelis, Floriana; Connick, Peter; Parker, Richard A; Plantone, Domenico; Doshi, Anisha; John, Nevin; Stutters, Jonathan; MacManus, David; Prados, Ferran; Marshall, Ian; Solanky, Bhavana; Samson, Rebecca S; Barkhof, Frederik; Ourselin, Sebastien; Braisher, Marie; Ross, Moira; Cranswick, Gina; Pavitt, Sue H; Gnanapavan, Sharmilee; Giovannoni, Gavin; Wheeler-Kingshott, Claudia AM Gandini; Hawkins, Clive; Sharrack, Basil; Bastow, Roger; Weir, Christopher J; Stallard, Nigel; Chandran, Siddharthan; Chataway, Jeremy

doi:10.3310/eme07030

Graphic version of this page | Change how these pages look

Journals Library

NHS NIHR - National Institute for Health and Care Research

Journals

Twitter
Facebook
LinkedIn
Email

An error occurred retrieving content to display, please try again.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Page Not Found

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Home >> Journals >> Efficacy and Mechanism Evaluation >> Volume {{metadata.Volume}} >> Issue {{metadata .Issue }}
Extended Research Article
i

Toolkit

View Award

Amiloride, fluoxetine and riluzole were not effective in reducing the brain volume loss in people with secondary progressive MS over 96 weeks.

Detailed Author information
Detailed Author information

Floriana De Angelis ¹, Peter Connick ², Richard A Parker ³, Domenico Plantone ¹, Anisha Doshi ¹, Nevin John ¹, Jonathan Stutters ¹, David MacManus ¹, Ferran Prados ^1,^4,⁵, Ian Marshall ², Bhavana Solanky ¹, Rebecca S Samson ¹, Frederik Barkhof ^1,^4,⁶, Sebastien Ourselin ⁷, Marie Braisher ¹, Moira Ross ³, Gina Cranswick ³, Sue H Pavitt ⁸, Sharmilee Gnanapavan ⁹, Gavin Giovannoni ⁹, Claudia AM Gandini Wheeler-Kingshott ^1,¹⁰, Clive Hawkins ¹¹, Basil Sharrack ¹², Roger Bastow ¹³, Christopher J Weir ³, Nigel Stallard ¹⁴, Siddharthan Chandran ², Jeremy Chataway ^1,^15,^*

¹ Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, Department of Neuroinflammation, Faculty of Brain Sciences, University College London, London, UK
² Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
³ Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
⁴ Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, UK
⁵ eHealth Centre, Universitat Oberta de Catalunya, Barcelona, Spain
⁶ Department of Radiology and Nuclear Medicine, Vrije Universiteit University Medical Centre, Amsterdam, the Netherlands
⁷ School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK
⁸ Dental Translational and Clinical Research Unit (part of the National Institute for Health Research Leeds Clinical Research Facility), University of Leeds, Leeds, UK
⁹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
¹⁰ Brain MRI 3T Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Mondino Foundation, Pavia, Italy
¹¹ Keele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, UK
¹² Department of Neuroscience, Royal Hallamshire Hospital, Sheffield, UK
¹³ UK MS Society patient representative, MS National Centre, London, UK
¹⁴ Statistics and Epidemiology, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
¹⁵ National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK
^* Corresponding author Email: j.chataway@ucl.ac.uk

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

[Image - Crossmark status check]

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

No responses have been published.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*
Name (title, first name, last name)*
Occupation / Job title*
Affiliation / Employer*
Email*
Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas
Statement of competing interestsWe believe that readers should be aware of any competing interests (conflicts of interest).The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.
If yes, please provide details below
Enter response title*
Enter CAPTCHA What is twelve minus two?*

By submitting your response, you are stating that you agree to the terms & conditions